Thermo Fisher has launched a new clinical registry to generate long-term real-world evidence and improve understanding of treatment outcomes for vitiligo patients.

Thermo Fisher Scientific has announced the launch of the PPD™ CorEvitas™ Vitiligo Registry, a new observational clinical registry designed to generate long-term real-world evidence for nonsegmental vitiligo (NSV). The registry will collect longitudinal data from adolescents and adults across the United States to help address gaps in understanding treatment effectiveness, patient outcomes and disease progression.

By capturing both clinician-reported and patient-reported outcomes, the registry will provide valuable insights into treatment patterns, disease burden and the long-term performance of approved therapies in routine clinical practice. The data will also support healthcare providers, researchers and life sciences organisations in making more informed clinical decisions.

As part of the wider CorEvitas Clinical Registries portfolio, the initiative aims to improve understanding of NSV while supporting future research and ultimately enhancing the quality of care and patient experience.

Read the full story here.